Pharmaceutical / Drug Definition :
Inhibits proliferation of Bcr-Abl tyrosine kinase, an abnormal chromosome protein found in most patients with chronic myeloid leukemia (CML). This inhibition suppresses tumor growth.
In the United States, Imatinib Mesylate is regulated by the U.S. Food and Drug Administration (FDA). FDA has specific requirements regarding the registration and listing of Imatinib Mesylate.
FDA Label Requirements and Exceptions
FDA Import Information
Imatinib Mesylate (Imatinib Mesylate Entry Refusal)
General U.S. Food and Drug Administration Guidelines for:
- Manufacturers Imatinib Mesylate (Imatinib Mesylate Suppliers)
- Processors Imatinib Mesylate
- Repackers Imatinib Mesylate
- Relabelers Imatinib Mesylate
- Exporters Imatinib Mesylate
- Importers Imatinib Mesylate
For more information about Imatinib Mesylate, simply click below:
U.S. FDA Regulations:
U.S. FDA Regulation: 21 C.F.R. Part 207
Registrar Corp assists businesses with U.S. FDA compliance. Certificates of Registration issued by Registrar Corp provide confirmation to industry that you are fulfilling U.S. FDA registration requirements. U.S. FDA does not issue or recognize Certificates of Registration. Registrar Corp is not affiliated with the U.S. Food and Drug Administration.